Apollo Healthtech listing plan: 2027, ₹25,000cr target

What Apollo Hospitals announced

Apollo Hospitals Enterprise Ltd said it plans to appoint promoter director Shobana Kamineni as the executive chairperson of Apollo Healthtech, the group’s medical equipment and healthcare solutions business that is being prepared for a separate stock market listing. The company said the proposed appointment is subject to shareholder approval. Kamineni currently serves as a promoter director on Apollo Hospitals’ board. The move is part of a wider restructuring aimed at unlocking value from different business lines. Apollo has said the Healthtech unit is expected to be listed as part of this exercise. The company also indicated it wants a stronger governance structure for the new entity ahead of the listing.

Shobana Kamineni’s proposed role and approvals

Apollo Hospitals said Kamineni would lead the next phase of growth for the medical devices and healthcare solutions business. The proposed appointment is linked to the composite scheme of arrangement for the separation and independent listing of Apollo Healthtech Limited. The company said the appointment would be made upon sanction of the scheme by the National Company Law Tribunal (NCLT), alongside other applicable approvals. It also stated it will seek shareholder approval for the terms, duration, and compensation related to the appointment. In addition to shareholder voting, the overall restructuring is subject to regulatory and stakeholder clearances.

What goes into Apollo Healthtech

Apollo Healthtech is described as covering medical equipment, healthcare solutions, and additional health-tech businesses within the group’s reorganisation. The unit will include the omnichannel pharmacy distribution (OCP) business, the Apollo 24/7 digital platform, and the telehealth division. It will also include the merged wholesale distribution arm, Keimed. Apollo Hospitals has framed the separation as a step toward creating distinct listed entities for its hospital operations and its health-tech and devices vertical. The company’s disclosures and reports around the scheme position Healthtech as a separate growth platform within the broader group.

Listing timeline: late FY27 and Q4 FY27 references

During a May earnings call, Apollo Hospitals said it expects the demerger and listing of Apollo Healthtech to be completed by late FY27, subject to regulatory and shareholder approvals. Separately, management guidance cited in the provided reports also referred to a potential listing by Q4 FY27 (January to March 2027), following completion of approvals. Some local-language reporting also indicated the group’s intent to list the demerged unit within the financial year, while the company’s earnings-call timeline points to late FY27. Across these references, the common element is that the listing is conditional on regulatory processes and shareholder votes. The scheme is also linked to scheduled stakeholder meetings.

Governance framework: independent board and nomination thresholds

Apollo Hospitals said Apollo Healthtech will have a governance framework anchored by an independent board. The company indicated that at least 50% of the unit’s board will comprise independent directors. Another disclosure in the provided material stated the Apollo Healthtech board will have 12 directors, of which six will be independent directors, aligned with SEBI requirements. Apollo also said nomination rights for promoters and investors will be linked to a proposed 10% shareholding threshold. This governance design is positioned as part of the preparations for a public market debut.

Revenue targets and the group’s financial context

Apollo Hospitals is targeting annualised revenue of around INR 25,000 crore for Apollo Healthtech by the time of listing. A separate market snapshot in the provided text also referred to a INR 25,000 crore annualised run-rate target by Q4 FY27. In the same snapshot, Apollo Hospitals’ consolidated revenue was cited as INR 25,229 crore for FY26. These figures place Apollo Healthtech’s stated revenue ambition alongside the group’s reported consolidated scale for FY26. Apollo’s communication ties the restructuring to a stated objective of unlocking value from its businesses, rather than changing the core hospital operations.

Scheme process and key dates mentioned

The restructuring is being executed through a scheme of arrangement, with multiple approvals required. One of the reported milestones is a creditor meeting scheduled for June 24, 2026, to approve the scheme of arrangement. The company has also stated that the appointment of the executive chairperson would be after NCLT sanction of the scheme. In addition, Apollo Hospitals said shareholder approval will be required for Kamineni’s appointment and for elements of the scheme where applicable. The timeline described in the reports indicates that regulatory, creditor, and shareholder steps will shape the sequencing toward the eventual listing.

Upside Agreement: disclosures cited in the scheme

Apollo Hospitals also provided additional information on an investor-funded Upside Agreement referenced in the scheme disclosures. The provided text states the Upside Agreement offers a maximum 9% upside for achieving a 4x MOIC, and that it requires public shareholder approval. Another disclosure stated the full funding for the agreement would be provided by a strategic investor named Rasmeley. The scheme, including the Upside Agreement, is described as being subject to approval by a majority of public shareholders in line with Regulation 26(6) of the SEBI LODR Regulations. The company also stated that Kamineni, in consultation with the board, would identify relevant employees who would be beneficiaries under the agreement.

What shareholders should track

Apollo Hospitals has said shareholders are expected to receive shares in the newly listed Apollo Healthtech entity in accordance with the swap ratio defined in the scheme of arrangement. While the swap ratio itself was not provided in the text, the mechanism described is a direct distribution of ownership in the new listed vertical to existing shareholders through the scheme. A separate report snippet included in the provided content stated that Apollo Hospitals shareholders would possess 42.1% of the new entity, directly and indirectly through Apollo Hospitals Enterprise. Investors are likely to focus on the final scheme terms as they are filed and approved, including the governance framework and the thresholds for nomination rights.

Key facts table

Why this restructuring matters

Apollo Hospitals has positioned the Healthtech separation as part of a broader effort to create clearer, separately listed business lines. The proposed leadership and governance structure suggests the group is preparing Apollo Healthtech to operate with public-market standards, including a board with at least half independent directors. At the same time, the company has retained promoter oversight through the proposed executive chairperson appointment, subject to shareholder approvals. The timeline and conditions highlighted in the disclosures reinforce that the listing is a process-driven event, dependent on NCLT, regulatory steps, and voting outcomes. The revenue targets set a measurable benchmark for how Apollo describes the scale it wants the new entity to reach by listing.

Conclusion

Apollo Hospitals’ plan to appoint Shobana Kamineni as executive chairperson of Apollo Healthtech is tied to the group’s proposed demerger and separate listing of the unit. The company has set an annualised revenue target of INR 25,000 crore by listing and outlined a governance structure with at least 50% independent directors and nomination rights linked to a 10% holding threshold. The scheme remains subject to approvals, including shareholder votes and NCLT sanction. A creditor meeting scheduled for June 24, 2026 is one of the next dated milestones cited in the disclosures, alongside the broader late-FY27 timeline referenced for completion.